A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (NCT06290141)
A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.
Who can join: Review the eligibility criteria below.
Location: Alabama Neurology Associates- Site Number : 8400019 — Homewood, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (135 Sites)
Showing the first 25 of 135 sites.
- Alabama Neurology Associates- Site Number : 8400019 — Homewood, Alabama
- Honor Health Scottsdale Osborn Medical Center- Site Number : 8400014 — Scottsdale, Arizona
- Keck School of Medicine of University of Southern California- Site Number : 8400002 — Los Angeles, California
- University of California Irvine Medical Center- Site Number : 8400007 — Orange, California
- IMMUNOe International Research Centers - Centennial- Site Number : 8400049 — Centennial, Colorado
- Yale University School of Medicine- Site Number : 8400018 — New Haven, Connecticut
- Nova Clinical Research - Bradenton- Site Number : 8400044 — Bradenton, Florida
- Design Neuroscience Center- Site Number : 8400053 — Miami Lakes, Florida
- AdventHealth Orlando- Site Number : 8400006 — Orlando, Florida
- AdventHealth Site Number : 8400006 — Orlando, Florida
- NorthShore University Health System - Glenbrook Hospital- Site Number : 8400024 — Glenview, Illinois
- University of Kansas Medical Center- Site Number : 8400010 — Kansas City, Kansas
- Ochsner Medical Center - Jefferson Highway- Site Number : 8400030 — New Orleans, Louisiana
- Johns Hopkins Hospital- Site Number : 8400015 — Baltimore, Maryland
- Massachusetts General Hospital- Site Number : 8400009 — Boston, Massachusetts
- Henry Ford Hospital- Site Number : 8400025 — Detroit, Michigan
- Michigan State University- Site Number : 8400038 — East Lansing, Michigan
- Washington University School of Medicine - Siteman Cancer Center- Site Number : 8400037 — St Louis, Missouri
- Profound Research- Site Number : 8400052 — Las Vegas, Nevada
- Dent Neurologic Institute - Amherst- Site Number : 8400039 — Amherst, New York
- Hospital for Special Surgery - Site Number : 8400041 — New York, New York
- Columbia University Irving Medical Center- Site Number : 8400003 — New York, New York
- Lenox Hill Hospital- Site Number : 8400051 — New York, New York
- Raleigh Neurology Associates- Site Number : 8400043 — Raleigh, North Carolina
- University of Cincinnati Medical Center- Site Number : 8400020 — Cincinnati, Ohio
📞 Contact the Study Coordinator
Phone: (800) 633-1610
Email: contact-us@sanofi.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Inflammatory Demyelinating Polyneuropathy
- Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP — Denton, Texas
- A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — Tampa, Florida
- A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP — Birmingham, Alabama
- A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) — Birmingham, Alabama
- A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP — Birmingham, Alabama
Explore by condition: All Chronic Inflammatory Demyelinating Polyneuropathy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.